ChengJWMColucciVJKalusJSSpinlerSA. Managing diabetes and preventing heart disease: have we found a safe and effective agent?Ann Pharmacother. 2019;53:510-522.
2.
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. JAMA. 2019;321:1720-1721. doi:10.1001/jama.2019.2702
3.
US Food and Drug Administration. FDA Drug Safety Communication: FDA Confirms Increased Risk of Leg and Foot Amputations With the Diabetes Medicine Canagliflozin (Invokana, Invokamet, Invokamet XR). Bethesda, MD: US Food and Drug Administration; 2017.
4.
Bersoff-MatchaSJChamberlainCCaoCKortepeterCChongWH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases [published online ahead of print May 7, 2019]. Ann Intern Med. doi:10.7326/M19-0085.
5.
US Food and Drug Administration. FDA Drug Safety Communication: FDA Warns that SGLT2 Inhibitors may Result in a Serious Condition of Too Much Acid in the Blood. Bethesda, MD: US Food and Drug Administration; 2015.
